Last quarter (Q2 2022), Biodexa Pharmaceuticals's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Biodexa Pharmaceuticals's net income was £―. See Biodexa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	£ 578.00K	£ 343.00K	£ 312.00K	£ 149.00K	£ 989.00K
Cost of Revenue	-	£ 4.65M	£ 6.07M	£ 7.84M	£ 9.36M	£ 8.33M
Gross Profit	-	£ -4.08M	£ -5.72M	£ -7.53M	£ -9.21M	£ -7.34M
Operating Expense	-	£ 2.92M	£ 4.95M	£ 3.79M	£ 2.60M	£ 4.44M
Operating Income	-	£ -7.00M	£ -10.67M	£ -11.32M	£ -11.81M	£ -11.78M
Net Non Operating Interest Income Expense	-	£ 44.00K	£ 33.00K	£ -89.00K	£ -585.00K	£ -94.00K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -6.11M	£ -23.47M	£ -10.92M	£ -12.40M	£ -12.97M
Tax Provision	-	£ -646.00K	£ -1.28M	£ -1.78M	£ -2.03M	£ -1.26M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -5.46M	£ -22.19M	£ -10.09M	£ -15.03M	£ -16.06M
Basic EPS	-	£ -1.40	£ -10.40	£ -55.00	£ -24.63	£ -30.54
Diluted EPS	-	£ -1.40	£ -10.40	£ -55.00	£ -24.63	£ -30.54
Basic Average Shares	-	£ 4.03M	£ 2.14M	£ 183.31K	£ 620.39K	£ 520.84K
Diluted Average Shares	-	£ 4.03M	£ 2.14M	£ 183.31K	£ 620.39K	£ 520.84K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	£ 0.00	£ 386.00K	£ 277.00K
Total Expenses	-	£ -7.58M	£ -11.01M	£ 11.63M	£ 11.96M	£ 12.77M
Net Income From Continuing And Discontinued Operation	-	£ -5.46M	£ -22.19M	£ -10.09M	£ -15.03M	£ -16.06M
Normalized Income	-	£ -6.75M	£ 384.00K	£ -9.54M	£ -10.37M	£ -10.71M
Interest Expense	-	£ 44.00K	£ 34.00K	£ 97.00K	£ 587.00K	£ 109.00K
EBIT	-	£ -6.06M	£ -23.44M	£ -10.83M	£ -11.81M	£ -12.86M
EBITDA	-	£ -6.06M	£ -23.44M	£ -9.54M	£ -10.36M	£ -10.30M

Currency in GBP

Biodexa Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing